Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia

Musiał, Jacek; Undas, Anetta; Gajewski, Piotr; Jankowski, Miłosz; Sydor, Wojciech; Szczeklik, Andrzej

doi:10.1016/s0167-5273(00)00439-3

Cited by 174 publications

(97 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was no correlation between any of the lipid profiles (TC, LDL-c, TG and HDL-c) and hsCRP level. The lack of correlation between hsCRP and lipid levels is consistent with results from other studies (Ridker et al, 1999;Musial et al, 2001;Jialal et al, 2001;Albert et al, 2001). Our data also did not find any correlation between hsCRP levels with other established cardiovascular risk factors such as age, gender, blood pressure, and smoking habit.…”

Section: Discussionsupporting

confidence: 92%

Evaluation of hsCRP, F2-Isoprostane and homocysteine levels in patients presenting with Primary Hypercholesterolemia in a tertiary referral teaching hospital

Rahman¹,

Yy²,

Sp³

et al. 2011

MHSJ

View full text Add to dashboard Cite

We conducted a cross-sectional study to investigate the levels of these biomarkers in primary hypercholesterolaemic patients. Fifty six primary hypercholesterolaemic patients, 29 familial hypercholesterolaemia (FH) and 27 non familial hypercholesterolaemia (NFH) age and gender matched control subjects were recruited for this study. Blood samples were taken for the analysis of serum fasting lipid profile, serum hsCRP, plasma Hcys and plasma 8-isoprostane. Serum Hcys levels were higher in all patients compared with control (mean + SD: 11.3 + 6.4 vs 8.6 + 3.3, p<0.05) with Hcys values being significantly higher in NFH group (mean + SD: 11.9 + 7.0 vs 8.6 + 3.3, p<0.05) compared with control. Serum hs-CRP were higher in NFH group (p<0.05) compared to control. Plasma 8-isoprostane levels of the primary hypercholesterolaemic patients were higher (mean + SEM: 1357.0 + 214.7 vs 398.0 + 20.5, p<0.05) compared to control and they were also higher in FH and NFH subgroups compared to control (mean + SEM: 1395.8+313.3 vs 398.0+20.5, p<0.05 and 1322.8+300.7 respectively). A significant correlation was seen between serum total cholesterol with serum Hcys and plasma isoprostane (r=0.6, p<0.001 and r=0.5, p<0.001 respectively). Correlation was also noted between serum LDL-c with serum Hcys (r=0.6, p<0.001) and plasma 8-isoprostane (r=0.5, p<0.05 In summary, this study has demonstrated that there is an significant association between hypercholesterolaemia with serum hsCRP, Hcys and plasma 8-isoprostane levels.

show abstract

Section: Discussionsupporting

confidence: 92%

Evaluation of hsCRP, F2-Isoprostane and homocysteine levels in patients presenting with Primary Hypercholesterolemia in a tertiary referral teaching hospital

Rahman¹,

Yy²,

Sp³

et al. 2011

MHSJ

View full text Add to dashboard Cite

show abstract

“…Decreases in leukocyte function antigen-1 may also relate. 26 An intriguing finding in this study was that treatment with simvastatin increased Lp(a). This finding has questionable clinical implications, although the role of Lp(a) as an independent risk factor for premature atherosclerotic vascular disease has been documented in several large studies.…”

Section: Discussionmentioning

confidence: 67%

Simvastatin Lowers C-Reactive Protein Within 14 Days

et al. 2002

View full text Add to dashboard Cite

Background-The early response of C-reactive protein to initiation of a hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) is not known. The purpose of this study was to determine the rate at which highly sensitive C-reactive protein (hsCRP) levels change after initiation of simvastatin and whether this occurs independently of the change in LDL cholesterol. Methods and Results-The study was a crossover, double-blind design including 40 subjects with elevated LDL cholesterol. Subjects were randomly assigned to 1 of 2 groups: simvastatin 40 mg for 14 days, then placebo for 14 days, or placebo first, then simvastatin. Simvastatin decreased LDL cholesterol by 56Ϯ4 mg/dL (PϽ0.0001) at day 7 and by an additional 8Ϯ3 mg/dL (Pϭ0.02) at day 14. Baseline log(hsCRP) levels were similar in the 2 groups. By day 14, log(hsCRP) was significantly lower in patients on simvastatin when compared with placebo (Pϭ0.011). Although there was no significant difference in fibrinogen levels, simvastatin produced a modest increase in log[lipoprotein(a)] (Pϭ0.03) at days 7 and 14. There were no relationships between the decrease in LDL cholesterol and the decrease in hsCRP. Conclusions-Simvastatin lowers hsCRP by 14 days, independent of its effect on LDL cholesterol. This rapid impact of a statin on hsCRP has potential implications in the management of acute coronary syndromes.

show abstract

“…In separate, randomized prospective studies of patients with hypercholesterolemia and hypertension, treatment with simvastatin resulted in decreased circulating IL-1␤, and IL-1␤ production by isolated PBMCs, respectively (82,83). Both atorvastatin and simvastatin significantly decrease levels of circulating IL-6 and TNF␣, in addition to IL-1␤, in patients with hypercholesterolemia (39,41,59,84). Carotid plaques resected from patients taking statins contain significantly lower concentrations of IL-6 (P ϭ 396 ABELES AND PILLINGER 0.0005), suggesting that statins do, indeed, alter local inflammation in atherosclerotic lesions (85).…”

Section: Statins As Antiinflammatory Drugs: Effects On Cells and Tissuesmentioning

confidence: 99%

Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?

Abeles

Pillinger

2006

Arthritis & Rheumatism

135

View full text Add to dashboard Cite

Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia

Cited by 174 publications

References 27 publications

Evaluation of hsCRP, F2-Isoprostane and homocysteine levels in patients presenting with Primary Hypercholesterolemia in a tertiary referral teaching hospital

Evaluation of hsCRP, F2-Isoprostane and homocysteine levels in patients presenting with Primary Hypercholesterolemia in a tertiary referral teaching hospital

Simvastatin Lowers C-Reactive Protein Within 14 Days

Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?

Contact Info

Product

Resources

About